Virus & Reservoirs Core

核心D：病毒和储库 摘要 病毒和储库核心（核心D）的使命是提供无与伦比的分子病毒学， 测序支持，服务，设施，咨询和培训宾夕法尼亚大学CFAR研究人员在校园里， 以及更广泛的艾滋病毒/艾滋病研究界。通过这种尖端的技术 结合积极主动的科学领导，核心D寻求在高优先级科学领域推进艾滋病研究， 方向在本报告所述期间，核心D已作出重大修改，以满足不断变化的 需要，机会和优先事项，并在艾滋病毒治疗领域领导前瞻性的研究议程， 持续性病毒储库的发病机制的理解。这些变化也包括新的服务 作为安装一个新的领导团队组成的博士.凯瑟琳酒吧（主任）和穆罕默德阿卜杜勒- Mohsen（联合主任）和三名高级艾滋病毒/艾滋病科学家作为核心研究员（Frederic Bushman博士， 比阿特丽斯·哈恩和乔治肖）为领导团队提供专业服务和指导。 为了支持其使命，病毒和水库核心提供：（1）最先进的分子病毒学服务 包括广泛的病毒库，规模经济的病毒检测服务，创新的细胞产品 逆转录病毒载体转导的离体扩增细胞的释放测定以支持创新的基因和细胞治疗 临床试验，以及定量实时和数字液滴PCR平台;（2）最先进的测序 分析支持服务，包括单基因组扩增、Illumina扩增子测序和 桑格平台，具有定制处理和分析支持，以及复杂人群的深度测序 （3）基于新传播/创始人SHIV（SIV/HIV嵌合体）的新服务 病毒，利用新一代SHIV的力量，为疫苗提供巨大的机会， 发病机制和治疗研究;（4）用于高度敏感和专业病毒分析的新平台，包括 病毒转录物的定量、前病毒整合、单拷贝病毒载量、单细胞分析和相关的 技术;（5）指导和教育适当应用这些新兴技术以及 （6）积极主动地开展外联和领导工作，以促进利用这些资源的研究。 技术，包括与艾滋病毒库和组织免疫学工作组的密切合作。 在本报告所述期间，核心D向119名调查员提供了支助， 并支持超过140个NIH资助的应用程序。展望即将到来的周期， 与临床、免疫学和非人灵长类核心以及储库和组织密切合作 免疫学SWG，核心D将扩大其服务，以促进基础和转化实验室研究， 在非人类灵长类动物中的临床研究，以及首次在人类中进行的研究HIV宿主、病毒持久性 治疗策略。

Core D: Virus and Reservoirs ABSTRACT The mission of the Virus and Reservoirs Core (Core D) is to provide unparalleled molecular virology and sequencing support, services, facilities, consultation, and training to Penn CFAR investigators on campus, as well as the HIV/AIDS research community more broadly. Through this cutting-edge enabling technology combined with proactive scientific leadership, Core D seeks to advance AIDS research in high priority scientific directions. In the current reporting period, Core D has made substantial changes to both meet evolving needs, opportunities and priorities, and lead a forward-looking research agenda in the area of HIV cure, pathogenesis understanding of persistent viral reservoirs. These changes include new services as well as installation of a new leadership team comprised of Drs. Katharine Bar (Director) and Mohamed Abdel- Mohsen (Co-Director), and three senior HIV/AIDS scientists as Core Investigators (Drs. Frederic Bushman, Beatrice Hahn and George Shaw) to provide both specialized services and mentorship to the leadership team. To support its mission, the Virus and Reservoirs Core provides: (1) State-of-the-art molecular virology services including an extensive virus repository, viral assay services for economy of scale, an innovative cell product release assay for retroviral vector transduced ex vivo expanded cells to support innovative gene- and cell-therapy clinical trials, and quantitative real-time and digital droplet PCR platforms; (2) State-of-the-art sequencing services with analytical support, including Single Genome Amplification, amplicon sequencing by Illumina and Sanger platforms with custom processing and analytic support, and deep sequencing for complex populations or integration site analysis; (3) A new service based on novel transmitted/founder SHIV (SIV/HIV chimeric) viruses, to leverage the power of a new generation of SHIVs with tremendous opportunity for vaccine, pathogenesis and cure research; (4) Novel platforms for highly sensitive and specialized viral analysis including quantification of viral transcripts, proviral integration, single-copy viral load, single-cell analysis and related techniques; (5) Mentoring and education in appropriate application of these emerging technologies as well as training in implementation; and (6) Proactive outreach and leadership to promote research that exploits these technologies, including close collaboration with the HIV Reservoirs & Tissue Immunology SWG. In the current reporting period, Core D provided support to 119 investigators, generated over $5,000,000 in chargebacks, and supported more than 140 NIH-funded applications. Looking ahead to the upcoming cycle, in close collaboration with the Clinical, Immunology and Nonhuman Primate Cores and the Reservoirs and Tissue Immunology SWG, Core D will expand its services to galvanize basic and translational laboratory research, pre- clinical studies in nonhuman primates, and first-in-human clinical trials studying HIV reservoirs, virus persistence, and cure strategies.